Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FKKE2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,980
Award facts
- Contract value 100% obligated
- $13,979.52 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a firm fixed-price delivery order valued at $13,979.52 to DMS Pharmaceutical Group Inc. for Xolair 300 mg/2 ml auto-injector units. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was awarded this delivery order on December 2, 2025, with an ultimate completion date of December 23, 2025. The award carries no set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical support to Department of Defense military healthcare facilities worldwide.
The PPV-G GEN V contract, awarded to DMS Pharmaceutical Group on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, structured as a 30-month base period with three 30-month option periods. Under this master contract framework, DLS maintains the authority to issue delivery orders for an extensive portfolio of pharmaceutical products including branded and generic prescription medications, biologics, vaccines, and medical consumables. The current delivery order for Xolair—a biologic immunosuppressant commonly used for moderate-to-severe asthma and chronic urticaria treatment—represents routine pharmaceutical fulfillment under this broader strategic supplier arrangement supporting military medical operations globally.
Quick answers
Who was awarded contract SPE2DR26FKKE2?
SPE2DR26FKKE2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 2, 2025.
How much is contract SPE2DR26FKKE2 worth?
The government has obligated $13,980 on SPE2DR26FKKE2.
Is contract SPE2DR26FKKE2 an order under another contract?
Yes. SPE2DR26FKKE2 is a delivery order under SPE2DR25D9367, an indefinite delivery contract.
Was contract SPE2DR26FKKE2 competed?
The extent of competition for SPE2DR26FKKE2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award